89bio, Inc. (ETNB) Shareholders to Receive Up to $3.5B Total in Roche Buyout Deal
89bio, Inc.
89Bio Inc. (ETNB)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 19,889,683 | $195,316,687 | 3.29% | |
| 2. | Suvretta Capital Management Aaron Cowen | 14,210,000 | $139,542,200 | -1% | 4.21% |
| 3. | Deep Track Capital David Kroin | 9,500,000 | $93,290,000 | +2% | 2.99% |
| 4. | VenBio Select Advisor Kurt Von Emster | 6,750,000 | $66,285,000 | +7% | 1.16% |
| 5. | Citadel Investment Group Ken Griffin | 3,836,892 | $37,678,279 | -25% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.75 | 5,714,285 | $49,999,993.75 | 19,554,319 | 2025-01-30 | Filing | |
| $6.71 | 10,000 | $67,100.00 | 25,000 | 2025-01-22 | Filing | |
| $6.55 | 5,000 | $32,750.00 | 15,000 | 2025-01-21 | Filing | |
| $7.89 | 5,000 | $39,450.00 | 471,236 | 2024-12-06 | Filing | |
| $8.00 | 10,000 | $80,000.00 | 10,000 | 2024-12-05 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $11.02 | 10,461 | $115,280.22 | 309,364 | 2025-07-15 | Filing | |
| $5.95 | 15,329 | $91,207.55 | 328,323 | 2025-04-15 | Filing | |
| $6.49 | 10,963 | $71,149.87 | 271,833 | 2025-01-15 | Filing | |
| $8.12 | 27,955 | $226,994.60 | 187,796 | 2024-10-30 | Filing | |
| $10.91 | 52,718 | $575,153.38 | 459,171 | 2024-04-01 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 242,716 | $3,567,925 | 0% | |
| 2. | 242,557 | $3,565,588 | 0% | |
| 3. | 163,914 | $2,409,536 | 0.32% | |
| 4. | 30,759 | $452,157 | 0.04% | |
| 5. | 21,885 | $321,709 | 0.01% |
News See All
12 Best Performing Healthcare Stocks to Buy Right Now
Spending on healthcare in the US is predicted to hit $5.3 trillion this year, making it one of the largest in the world.
89Bio (ETNB) Soars 86 Percent to Historic High on $3.5-Billion Roche Merger
In a statement, Roche said it entered into a definitive agreement to acquire 89bio Inc.
Top 10 Stocks Under $10 That Could Triple
The Bureau of Labor Statistics reported that only 22,000 jobs were added in August, much less than the 75,000 jobs that economists polled by Dow Jones had expected.
89bio, Inc. (ETNB) Reports Second-Quarter Results; Leerink Partners and Citi Maintain ‘Buy’ Ratings
On August 7, 2025, 89bio, Inc. (NASDAQ:ETNB) reported its Q2 2025 results.
11 Best Single Digit Stocks to Buy According to Hedge Funds
The winning streak of U.S. stocks extended on Wednesday, August 13, 2025, with the S&P 500 and Nasdaq reaching fresh record highs for the second day in a row.
10 Best Low Priced Biotech Stocks to Buy Now
On May 8, Michael Yee, Senior Biotech Analyst at Jefferies, appeared on CNBC to discuss how tariffs and policy risks are pressuring the biotech industry, while simultaneously iterating that low valuations...
10 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds
The biotechnology sector is expanding quickly due to rising demand for novel therapies, technological advances, and government assistance.
13 Best Biotech Stocks To Buy Under $20
In this article, we're going to take a look at 13 best biotech stocks to buy under $20.
5 Stocks Insiders are Buying Now
Satellite communication and internet services company EchoStar Corp (NASDAQ:SATS) ranks fifth in our list of the stocks with the highest insider purchasing activity recently.
Hedge Fund Resource Center Billionaire Hedge Funds
